Risankizumab

Risankizumab is a humanized monoclonal antibody designed for the treatment of psoriasis. It was developed by AbbVie, a global biopharmaceutical company, and was approved by the FDA in the United States in 2019 under the brand name Skyrizi.

Mechanism of Action[edit | edit source]

Risankizumab works by selectively binding to the p19 subunit of interleukin 23, a cytokine involved in inflammatory and immune responses. By inhibiting the action of interleukin 23, Risankizumab reduces the inflammation and other symptoms associated with psoriasis.

Clinical Trials[edit | edit source]

Risankizumab has undergone several clinical trials to evaluate its safety and efficacy. In Phase 3 trials, Risankizumab demonstrated superior efficacy compared to Ustekinumab, another monoclonal antibody used for the treatment of psoriasis.

Side Effects[edit | edit source]

Common side effects of Risankizumab include upper respiratory infections, headache, and fatigue. Serious side effects may include severe infections and allergic reactions.

Approval[edit | edit source]

Risankizumab was approved by the FDA in April 2019 for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy. It has also been approved in the European Union and other countries.